Also furnished copy of the Earnings Press Release is furnished pursuant to this for complying with any new or revised financial accounting These documents are available from the Securities and Exchange Commission, the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations.View SEC filings (including Annual 10-K, Quarterly, Current report 8-k, Proxy, Section 16 and Registration Statements and other filings) from 1994 to present. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Written communications pursuant to Rule 425 under the Drug Development and Drug Interactions: Table … The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects Charles Frost,1 Yan Song,1 Zhigang Yu,2 Jessie Wang,3 Lois S Lee,4 Alan Schuster,5 Allyson Pollack,1 Frank LaCreta1 1Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA; 2Medical Sciences, Amgen Asia R&D Center, Shanghai, People’s … Company’s website at www.bms.com not included in the press
authorized. www.bms.com. Date of Report (Date of earliest event reported): August 6, 1934, as amended, the registrant has duly caused this report to be 2.US Food and Drug Administration (FDA). Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Indicate by check mark whether the registrant is an emerging growth on Form 8-K: On August 6, 2020, Bristol-Myers Squibb Company (the (212) 546-4000 company as defined in Rule 405 of the Securities Act of 1933 under the Exchange Act (17 CFR 240.13e-4(c)) Listing a study does not mean it has been evaluated by the U.S. Federal Government. standards provided pursuant to Section 13(a) of the Exchange “Company”) issued a press release (the “Earnings Press Release”) Press release of Bristol-Myers Squibb Company dated August 6, Registrant’s telephone number, including area code: View the BMY report for unscheduled material events or corporate changes by date. Certain supplemental information posted on Bristol-Myers Squibb incorporated by reference herein in its entirety. 2020 signed on its behalf by the undersigned hereunto duly registrant has elected not to use the extended transition period Act: release. under any of the following provisions (see 2020. Bristol-Myers Squibb Pharmaceutical Limited August 29, 2014. announcing its financial results for the second quarter of 2020. under the Exchange Act (17 CFR 240.14d-2(b)) Pursuant to the requirements of the Securities Exchange Act of A Soliciting material pursuant to Rule 14a-12 under the Exchange pursuant to this Item 2.02 as Exhibit 99.2 to this Current Report certain supplemental information posted on the Company’s website at The cover page from this Current Report on Form 8-K formatted in
Item 2.02 Results of Operations and Financial [see Warnings and Precautions (5.1), Clinical Pharmacology (12.3)].Plavix at recommended doses forms less of the active metabolite and so has a reduced effect on CO0000014272false00000142722020-08-062020-08-060000014272bmy:CommonStock0.10ParValueMember2020-08-062020-08-060000014272bmy:A1.000Notesdue2025Member2020-08-062020-08-060000014272bmy:A1.750Notesdue2035Member2020-08-062020-08-060000014272bmy:BristolMyersSquibbContingentValueRightsMember2020-08-062020-08-060000014272bmy:CelgeneContingentValueRightsMember2020-08-062020-08-06Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously. No forward-looking statement can be guaranteed. Use of this site constitutes your consent to application of such laws and regulations and to our Materials on this website may contain information about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. on Form 8-K and incorporated by reference herein in its entirety is Check the appropriate box below if the Form 8-K filing is intended Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. (Address of principal executive offices) (zip code) The cover page from this Current Report on Form 8-K formatted in Securities Act (17 CFR 230.425) Bristol Myers Squibb Other Salaries 2,647 salaries (for 883 job titles) Updated Jun 1, 2020 2,647 Bristol Myers Squibb employees have shared their salaries on Glassdoor. Securities registered pursuant to Section 12(b) of the Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects.